← Leaderboards
Steven M Kawut
Columbia University Health Sciences
$28,347,465
Attributed
$34,632,029
Total exposure
13
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$34,632,029 · 13
By mechanism
R01$26,960,469 · 7
UM1$5,115,102 · 1
K24$1,565,924 · 1
K23$641,344 · 1
R03$322,000 · 1
M01$27,190 · 2
Top collaborators
- Michael Todd Fallon6 shared
- Roham Zamanian5 shared
- Michael B Fallon3 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Richard W Foltin$21,307,956
- Henry Michael Spotnitz$5,271,689
- John L Thompson$26,060,206
- Michael Argenziano$2,801,265
- Andrea B Troxel$185,878,739
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungPulmonary HypertensionClinical TrialsAffectPatient Oriented ResearchPulmonary Arterial HypertensionBlood VesselsFundingCessation Of LifeWalkingMedicalHigh RiskHypertensionVascular DiseasesProgramsRandomized Clinical TrialsExerciseLiver DiseasesCirrhosisAnimal ModelResearch PersonnelLeadNovel TherapeuticsProspective
Grant awards (59)
Physical Activity in Pulmonary Arterial Hypertension (ACTiPH)$913,900
R01 · FY2025 · HL · contact PI
Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension$714,004
R01 · FY2025 · HL · contact PI
Physical Activity in Pulmonary Arterial Hypertension (ACTiPH)$1,251,085
R01 · FY2024 · HL · contact PI
Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension$683,215
R01 · FY2024 · HL · contact PI
Physical Activity in Pulmonary Arterial Hypertension (ACTiPH)$1,161,165
R01 · FY2023 · HL · contact PI
Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension$692,797
R01 · FY2023 · HL · contact PI
Physical Activity in Pulmonary Arterial Hypertension (ACTiPH)$1,106,460
R01 · FY2022 · HL · contact PI
Novel Mechanisms of Hepatopulmonary Syndrome$797,645
R01 · FY2022 · HL · contact PI
Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension$735,810
R01 · FY2022 · HL · contact PI
Physical Activity in Pulmonary Arterial Hypertension (ACTiPH)$1,123,529
R01 · FY2021 · HL · contact PI
Anastrozole in Pulmonary Arterial Hypertension (AIPH2) - CCC (Lead)$1,064,328
R01 · FY2021 · HL · contact PI
Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension$851,205
R01 · FY2021 · HL · contact PI
Novel Mechanisms of Hepatopulmonary Syndrome$769,513
R01 · FY2021 · HL · contact PI
Anastrozole in Pulmonary Arterial Hypertension (AIPH2) - CCC (Lead)$1,094,913
R01 · FY2020 · HL · contact PI
Novel Mechanisms of Hepatopulmonary Syndrome$767,433
R01 · FY2020 · HL · contact PI
Mentored Patient-Oriented Research in Pulmonary Arterial Hypertension$119,427
K24 · FY2020 · HL · contact PI
Anastrozole in Pulmonary Arterial Hypertension (AIPH2) - CCC (Lead)$1,106,076
R01 · FY2019 · HL · contact PI
Novel Mechanisms of Hepatopulmonary Syndrome$769,998
R01 · FY2019 · HL · contact PI
Mentored Patient-Oriented Research in Pulmonary Arterial Hypertension$119,427
K24 · FY2019 · HL · contact PI
Anastrozole in Pulmonary Arterial Hypertension (AIPH2) - CCC (Lead)$1,114,479
R01 · FY2018 · HL · contact PI
Novel Mechanisms of Hepatopulmonary Syndrome$834,604
R01 · FY2018 · HL · contact PI
Mentored Patient-Oriented Research in Pulmonary Arterial Hypertension$119,427
K24 · FY2018 · HL · contact PI
Anastrozole in Pulmonary Arterial Hypertension (AIPH2) - CCC (Lead)$1,160,837
R01 · FY2017 · HL · contact PI
Mentored Patient-Oriented Research in Pulmonary Arterial Hypertension$119,427
K24 · FY2017 · HL · contact PI
Estrogen signaling in portopulmonary hypertension$782,815
R01 · FY2016 · HL · contact PI
Mentored Patient-Oriented Research in Pulmonary Arterial Hypertension$119,427
K24 · FY2016 · HL · contact PI
Sorafenib for Hepatopulmonary Syndrome$2,037,215
UM1 · FY2015 · HL · contact PI
Estrogen signaling in portopulmonary hypertension$744,654
R01 · FY2015 · HL · contact PI
Aromatase Inhibitors in Pulmonary Vascular Complications of Liver Disease$193,758
K24 · FY2015 · HL · contact PI
Estrogen signaling in portopulmonary hypertension$12,267
R01 · FY2015 · HL · contact PI
Sorafenib for Hepatopulmonary Syndrome$2,014,988
UM1 · FY2014 · HL · contact PI
Estrogen signaling in portopulmonary hypertension$704,738
R01 · FY2014 · HL · contact PI
Aromatase Inhibitors in Pulmonary Vascular Complications of Liver Disease$193,758
K24 · FY2014 · HL · contact PI
Sorafenib for Hepatopulmonary Syndrome$1,062,899
UM1 · FY2013 · HL · contact PI
Estrogen signaling in portopulmonary hypertension$694,908
R01 · FY2013 · HL · contact PI
Aromatase Inhibitors in Pulmonary Vascular Complications of Liver Disease$193,757
K24 · FY2013 · HL · contact PI
Estrogen signaling in portopulmonary hypertension$837,614
R01 · FY2012 · HL · contact PI
Aromatase Inhibitors in Pulmonary Vascular Complications of Liver Disease$193,758
K24 · FY2012 · HL · contact PI
Aromatase Inhibitors in Pulmonary Vascular Complications of Liver Disease$193,758
K24 · FY2011 · HL · contact PI
Endothelial Dysfunction and the RV in the Multi-Ethnic Study of Atherosclerosis$387,815
R01 · FY2010 · HL · contact PI
A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension$618,947
R01 · FY2009 · HL · contact PI
Endothelial Dysfunction and the RV in the Multi-Ethnic Study of Atherosclerosis$404,624
R01 · FY2009 · HL · contact PI
A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension$163,385
R01 · FY2009 · HL · contact PI
A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension$609,765
R01 · FY2008 · HL · contact PI
Endothelial Dysfunction and the RV in the Multi-Ethnic Study of Atherosclerosis$597,988
R01 · FY2008 · HL · contact PI
Endothelial Dysfunction and the RV in the Multi-Ethnic Study of Atherosclerosis$651,279
R01 · FY2007 · HL · contact PI
A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension$604,283
R01 · FY2007 · HL · contact PI
Aspirin and Simvastatin--Pulmonary Arterial Hypertension$432,391
R01 · FY2006 · HL · contact PI
Genetic Risk Factors for Portopulmonary Hypertension$161,000
R03 · FY2005 · DK
Neurohormonal Activation in Pulmonary Hypertension$127,791
K23 · FY2005 · HL
NEUROHORMONES IN PULMONARY HYPERTENSION$5,484
M01 · FY2005 · RR
ASPIRIN AND CLOPIDOGREL IN PH$322
M01 · FY2005 · RR
Genetic Risk Factors for Portopulmonary Hypertension$161,000
R03 · FY2004 · DK
Neurohormonal Activation in Pulmonary Hypertension$127,791
K23 · FY2004 · HL
Aspirin and Clopidogrel in PH$14,719
M01 · FY2004 · RR
Neurohormones in Pulmonary Hypertension$6,665
M01 · FY2004 · RR
Neurohormonal Activation in Pulmonary Hypertension$127,791
K23 · FY2003 · HL
Neurohormonal Activation in Pulmonary Hypertension$127,791
K23 · FY2002 · HL
Neurohormonal Activation in Pulmonary Hypertension$130,180
K23 · FY2001 · HL